Download PDF
Int J Angiol 2024; 33(02): 095-100
DOI: 10.1055/s-0044-1782537
Review Article

Anticoagulation in the Management of Acute Pulmonary Embolism—A Review

Raul del Toro Mijares
1   Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas
,
Adrian Rojas Murguia 
1   Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas
,
Mateo Porres-Aguilar
1   Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas
,
Debabrata Mukherjee 
1   Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Venous thromboembolism (VTE) is a very frequent cardiovascular entity that encompasses deep vein thrombosis and pulmonary embolism (PE). This last entity represents a major cause of cardiovascular morbidity and mortality. The incidence of PE and the rate of PE-related morbidity significantly increase with age, race, and underlying medical conditions, such as malignancy. Given the recent advances in diagnostic strategies and algorithms, patients can be risk assessed and treated promptly to avoid disease progression. Anticoagulation is the mainstay of treatment for acute PE that is not hemodynamically unstable. Direct oral anticoagulants, such as apixaban, rivaroxaban, or edoxaban, are currently the preferred agents for the treatment of patients who present with acute PE or for long-term treatment. Treatment duration should be continued for at least 3 months, and all patients should be assessed for extended duration of therapy based on the precipitating factors that led to the development of the VTE. Novel anticoagulant agents targeting factor XI/XIa are currently being investigated in phases 2 and 3 clinical trials, representing an attractive option in anticoagulation therapies in patients with VTE. For hemodynamically unstable patients, systemic thrombolysis is the treatment of choice, and it may also be of benefit—in reduced dose—for patients with intermediate to high risk who are at risk of hemodynamic collapse.

Keywords

anticoagulation - factor Xa - deep vein thrombosis - pulmonary embolism - thrombolysis - low-molecular-weight heparin - warfarin


Publication History

Article published online:
12 March 2024

© 2024. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. Am J Med 2016; 129 (08) 879.e19-879.e25
    CrossrefPubMedSearch in Google Scholar
  • 2 Sista AK, Miller LE, Kahn SR, Kline JA. Persistent right ventricular dysfunction, functional capacity limitation, exercise intolerance, and quality of life impairment following pulmonary embolism: systematic review with meta-analysis. Vasc Med 2017; 22 (01) 37-43
    CrossrefPubMedSearch in Google Scholar
  • 3 Pengo V, Lensing AWA, Prins MH. et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350 (22) 2257-2264
    CrossrefPubMedSearch in Google Scholar
  • 4 Søgaard KK, Schmidt M, Pedersen L, Horváth-Puhó E, Sørensen HT. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 2014; 130 (10) 829-836
    CrossrefPubMedSearch in Google Scholar
  • 5 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334 (7595): 674
    CrossrefPubMedSearch in Google Scholar
  • 6 Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78 (04) 412-421
    CrossrefPubMedSearch in Google Scholar
  • 7 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedSearch in Google Scholar
  • 8 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedSearch in Google Scholar
  • 9 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedSearch in Google Scholar
  • 10 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedSearch in Google Scholar
  • 12 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedSearch in Google Scholar
  • 13 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedSearch in Google Scholar
  • 14 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary. Chest 2021; 160 (06) 2247-2259
    CrossrefPubMedSearch in Google Scholar
  • 15 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedSearch in Google Scholar
  • 16 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedSearch in Google Scholar
  • 17 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedSearch in Google Scholar
  • 18 Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 (11) 1354-1373
    CrossrefPubMedSearch in Google Scholar
  • 19 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedSearch in Google Scholar
  • 20 Sanchez O, Charles-Nelson A, Ageno W. et al; PEITHO-3 Investigators. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost 2022; 122 (05) 857-866
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Porres-Aguilar M, Rosovsky RP, Rivera-Lebron BN. et al. Pulmonary embolism response teams: changing the paradigm in the care for acute pulmonary embolism. J Thromb Haemost 2022; 20 (11) 2457-2464
    CrossrefPubMedSearch in Google Scholar
  • 22 Prakash S, Mares AC, Porres-Aguilar M, Mukherjee D, Barnes GD. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: a narrative review. Vasc Med 2024; 29 (01) 85-92
    CrossrefPubMedSearch in Google Scholar
  • 23 Chan NC, Weitz JI. New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors. Arterioscler Thromb Vasc Biol 2023; 43 (10) 1755-1763
    CrossrefPubMedSearch in Google Scholar
  • 24 Fredenburgh JC, Weitz JI. News at XI: moving beyond factor Xa inhibitors. J Thromb Haemost 2023; 21 (07) 1692-1702
    CrossrefPubMedSearch in Google Scholar
  • 25 A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE. ClinicalTrials.gov identifier: NCT05171049. Accessed December 5, 2023 at: https://www.clinicaltrials.gov/study/NCT05171049
    PubMed
  • 26 A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE. ClinicalTrials.gov identifier: NCT05171075. Accessed December 5, 2023 at: https://www.clinicaltrials.gov/study/NCT05171075
    PubMed
  • 27 A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis. ClinicalTrials.gov identifier: NCT04465760. Accessed December 5, 2023 at: https://www.clinicaltrials.gov/study/NCT04465760
    PubMed
  • 28 Kumbhani DJ. A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - AZALEA-TIMI 71. American College of Cardiology. Accessed December 5, 2023 at: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/10/22/46/azalea-timi-71
    PubMed
  • 29 Porres-Aguilar M. ThromboprophylaXIs with factor XI/XIa inhibitors for venous thromboembolism. J Vasc Bras 2023; 22: e20230051
    CrossrefPubMedSearch in Google Scholar